Guggenheim Maintains Buy on Janux Therapeutics, Lowers Price Target to $58

Benzinga Newsdesk www.benzinga.com Negative 72.4%

Neg 72.4% Neu 0% Pos 0%

Guggenheim analyst Brad Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $68 to $58.